MX2024005399A - Combinaciones farmaceuticas para el tratamiento de hbv. - Google Patents
Combinaciones farmaceuticas para el tratamiento de hbv.Info
- Publication number
- MX2024005399A MX2024005399A MX2024005399A MX2024005399A MX2024005399A MX 2024005399 A MX2024005399 A MX 2024005399A MX 2024005399 A MX2024005399 A MX 2024005399A MX 2024005399 A MX2024005399 A MX 2024005399A MX 2024005399 A MX2024005399 A MX 2024005399A
- Authority
- MX
- Mexico
- Prior art keywords
- hbv
- pharmaceutical combinations
- treatment
- relates
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
- C12N2310/3125—Methylphosphonates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21207715 | 2021-11-11 | ||
| PCT/EP2022/081355 WO2023083906A2 (en) | 2021-11-11 | 2022-11-09 | Pharmaceutical combinations for treatment of hbv |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024005399A true MX2024005399A (es) | 2024-05-23 |
Family
ID=78598914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024005399A MX2024005399A (es) | 2021-11-11 | 2022-11-09 | Combinaciones farmaceuticas para el tratamiento de hbv. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250263705A2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4430184A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024544532A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240101580A9 (cg-RX-API-DMAC7.html) |
| CN (1) | CN118284695A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022384619A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3234478A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL312635A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024005399A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023083906A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240131441A (ko) | 2022-01-10 | 2024-08-30 | 오스퍼바이오 테라퓨틱스 인크. | B형 간염 바이러스(hbv) 발현의 조절 |
| EP4756027A1 (en) * | 2023-08-04 | 2026-06-10 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Double-stranded ribonucleic acid targeting pd-l1 |
| TW202612708A (zh) * | 2024-05-22 | 2026-04-01 | 美商浩博生物醫藥有限公司 | 組合治療 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| EP1015469B2 (en) | 1997-09-12 | 2015-11-18 | Exiqon A/S | Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues |
| BRPI0008131B8 (pt) | 1999-02-12 | 2021-05-25 | Daiichi Sankyo Co Ltd | composto ou um sal deste, análogo de oligonucleotídeo, composição farmacêutica, sonda para um gene,iniciador para começar a amplificação, uso de um análogo de oligonucleotídeo ou de um sal deste farmacologicamente aceitável, agente antisentido, e, agente antígeno |
| ATE356824T1 (de) | 1999-05-04 | 2007-04-15 | Santaris Pharma As | L-ribo-lna analoge |
| US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
| KR20080023768A (ko) | 2000-03-30 | 2008-03-14 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | Rna 간섭의 rna 서열 특이적인 매개체 |
| CN100523215C (zh) | 2000-12-01 | 2009-08-05 | 马普科技促进协会 | 介导rna干涉的小rna分子 |
| US20050159378A1 (en) | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA) |
| WO2003040395A2 (en) | 2001-11-07 | 2003-05-15 | Applera Corporation | Universal nucleotides for nucleic acid analysis |
| EP2284269B1 (en) | 2002-11-18 | 2017-08-09 | Roche Innovation Center Copenhagen A/S | Antisense design |
| AU2004221760B2 (en) | 2003-03-21 | 2010-03-18 | Roche Innovation Center Copenhagen A/S | Short interfering RNA (siRNA) analogues |
| US20070265220A1 (en) | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| ES2459368T3 (es) | 2004-12-17 | 2014-05-09 | Anadys Pharmaceuticals, Inc. | Compuestos de 3H-oxazolo y 3H-tiazolo[4,5-d]pirimidin-2-ona 3,5-disustituidos y 3,5,7-trisustituidos y profármacos de los mismos |
| WO2007030167A1 (en) | 2005-09-02 | 2007-03-15 | Nastech Pharmaceutical Company Inc. | Modification of double-stranded ribonucleic acid molecules |
| WO2007085485A2 (en) | 2006-01-27 | 2007-08-02 | Santaris Pharma A/S | Lna modified phosphorothiolated oligonucleotides |
| DE602007009487D1 (de) | 2006-01-27 | 2010-11-11 | Isis Pharmaceutical Inc | 6-modifizierte bicyclische nukleinsäureanaloga |
| ES2556128T3 (es) | 2006-03-23 | 2016-01-13 | Roche Innovation Center Copenhagen A/S | ARN interfiriente pequeño internamente segmentado |
| EP2505646A1 (en) | 2006-05-05 | 2012-10-03 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of CRP |
| CA2651453C (en) | 2006-05-11 | 2014-10-14 | Isis Pharmaceuticals, Inc. | 5'-modified bicyclic nucleic acid analogs |
| US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
| EP2410053B2 (en) | 2006-10-18 | 2020-07-15 | Ionis Pharmaceuticals, Inc. | Antisense compounds |
| US8580756B2 (en) | 2007-03-22 | 2013-11-12 | Santaris Pharma A/S | Short oligomer antagonist compounds for the modulation of target mRNA |
| DK2170917T3 (da) | 2007-05-30 | 2012-10-08 | Isis Pharmaceuticals Inc | N-Substituerede bicycliske nukleinsyreanaloge med aminomethylenbro |
| WO2008154401A2 (en) | 2007-06-08 | 2008-12-18 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
| AU2008272918B2 (en) | 2007-07-05 | 2012-09-13 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
| WO2009067647A1 (en) | 2007-11-21 | 2009-05-28 | Isis Pharmaceuticals, Inc. | Carbocyclic alpha-l-bicyclic nucleic acid analogs |
| WO2010033225A2 (en) | 2008-09-22 | 2010-03-25 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for the specific inhibition of gene expression by dsrna possessing modifications |
| WO2010039543A2 (en) | 2008-09-23 | 2010-04-08 | Traversa Therapeutics, Inc. | Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference |
| WO2010036698A1 (en) | 2008-09-24 | 2010-04-01 | Isis Pharmaceuticals, Inc. | Substituted alpha-l-bicyclic nucleosides |
| KR20110110776A (ko) | 2008-12-18 | 2011-10-07 | 다이서나 파마수이티컬, 인크. | 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법 |
| WO2010093788A2 (en) | 2009-02-11 | 2010-08-19 | Dicerna Pharmaceuticals, Inc. | Multiplex dicer substrate rna interference molecules having joining sequences |
| US8927513B2 (en) | 2009-07-07 | 2015-01-06 | Alnylam Pharmaceuticals, Inc. | 5′ phosphate mimics |
| EP2462153B1 (en) | 2009-08-06 | 2015-07-29 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
| US9725479B2 (en) | 2010-04-22 | 2017-08-08 | Ionis Pharmaceuticals, Inc. | 5′-end derivatives |
| US8846637B2 (en) | 2010-06-08 | 2014-09-30 | Isis Pharmaceuticals, Inc. | Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
| US10017764B2 (en) | 2011-02-08 | 2018-07-10 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
| US20140303235A1 (en) | 2011-08-11 | 2014-10-09 | Isis Pharmaceuticals, Inc. | Linkage modified gapped oligomeric compounds and uses thereof |
| EP2850092B1 (en) | 2012-04-09 | 2017-03-01 | Ionis Pharmaceuticals, Inc. | Tricyclic nucleic acid analogs |
| CA2889044A1 (en) | 2012-11-15 | 2014-05-22 | Roche Innovation Center Copenhagen A/S | Anti apob antisense conjugate compounds |
| EP2928877B1 (en) | 2012-12-06 | 2020-01-22 | Merck Sharp & Dohme Corp. | Disulfide masked prodrug compositions and methods |
| PL2992098T3 (pl) | 2013-05-01 | 2019-09-30 | Ionis Pharmaceuticals, Inc. | Kompozycje i sposoby modulowania ekspresji hbv i ttr |
| GB201408623D0 (en) | 2014-05-15 | 2014-07-02 | Santaris Pharma As | Oligomers and oligomer conjugates |
| CN107109405A (zh) | 2014-06-06 | 2017-08-29 | 索尔斯蒂斯生物有限公司 | 具有生物可逆性和非生物可逆性基团的多核苷酸构建体 |
| EP3204392A1 (en) | 2014-10-11 | 2017-08-16 | F. Hoffmann-La Roche AG | Compounds for use in the treatment of infectious diseases |
| TWI769565B (zh) | 2014-11-10 | 2022-07-01 | 美商阿尼拉製藥公司 | B型肝炎病毒(HBV)iRNA組成物及其用途方法 |
| HUE053704T2 (hu) | 2014-12-08 | 2021-07-28 | Hoffmann La Roche | 3-szubsztitutált 5-amino-6H-tiazolo[4,5-d]pirimidin-2,7-dion vegyületek vírusfertõzések kezelésére és megelõzésére |
| EP3865576A1 (en) | 2014-12-15 | 2021-08-18 | Dicerna Pharmaceuticals, Inc. | Ligand-modified double-stranded nucleic acids |
| CA3013683C (en) | 2016-03-14 | 2021-07-13 | F. Hoffmann-La Roche Ag | Oligonucleotides for reduction of pd-l1 expression |
| WO2018098328A1 (en) | 2016-11-23 | 2018-05-31 | Alnylam Pharmaceuticals, Inc. | Modified rna agents with reduced off-target effect |
| EP3684377B1 (en) | 2017-10-20 | 2022-12-07 | Dicerna Pharmaceuticals, Inc. | Methods for treating hepatitis b infection |
| MA55375A (fr) * | 2019-03-20 | 2022-01-26 | Arbutus Biopharma Corp | Méthodes thérapeutiques de traitement de l'hépatite b |
| EP4081639A1 (en) * | 2019-12-24 | 2022-11-02 | F. Hoffmann-La Roche AG | Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv |
| WO2021178612A1 (en) * | 2020-03-05 | 2021-09-10 | Janssen Pharmaceuticals, Inc. | Combination therapy for treating hepatitis b virus infection |
| JP2023536999A (ja) * | 2020-08-05 | 2023-08-30 | エフ. ホフマン-ラ ロシュ アーゲー | B型肝炎患者のオリゴヌクレオチド処置 |
-
2022
- 2022-11-09 AU AU2022384619A patent/AU2022384619A1/en active Pending
- 2022-11-09 EP EP22817176.5A patent/EP4430184A2/en active Pending
- 2022-11-09 JP JP2024527533A patent/JP2024544532A/ja active Pending
- 2022-11-09 KR KR1020247015280A patent/KR20240101580A9/ko active Pending
- 2022-11-09 CN CN202280074145.9A patent/CN118284695A/zh active Pending
- 2022-11-09 CA CA3234478A patent/CA3234478A1/en active Pending
- 2022-11-09 MX MX2024005399A patent/MX2024005399A/es unknown
- 2022-11-09 WO PCT/EP2022/081355 patent/WO2023083906A2/en not_active Ceased
- 2022-11-09 IL IL312635A patent/IL312635A/en unknown
-
2024
- 2024-05-09 US US18/659,831 patent/US20250263705A2/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240425859A1 (en) | 2024-12-26 |
| KR20240101580A (ko) | 2024-07-02 |
| JP2024544532A (ja) | 2024-12-03 |
| CN118284695A (zh) | 2024-07-02 |
| WO2023083906A2 (en) | 2023-05-19 |
| CA3234478A1 (en) | 2023-05-19 |
| IL312635A (en) | 2024-07-01 |
| AU2022384619A1 (en) | 2024-04-11 |
| KR20240101580A9 (ko) | 2025-12-10 |
| US20250263705A2 (en) | 2025-08-21 |
| EP4430184A2 (en) | 2024-09-18 |
| WO2023083906A3 (en) | 2023-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024006742A2 (es) | Compuestos terapéuticos para la infección por el virus del vih | |
| MX2021014742A (es) | Peptidomimeticos para el tratamiento de infecciones por coronavirus y picornavirus. | |
| MX2023011903A (es) | Tionucleosidos como agentes antivirales. | |
| BR112023000323A2 (pt) | Vacina combinada contra sars-cov-2 e influenza | |
| MX2022007908A (es) | Combinacion farmaceutica de un oligonucleotido terapeutico que actua sobre hbv y un agonista de tlr7 para el tratamiento de hbv. | |
| BR112022016413A2 (pt) | Método para o tratamento ou prevenção do coronavírus causado pelo vírus coronavírus da síndrome respiratória aguda grave 2, composto, e, uso de um composto | |
| CR20170424A (es) | Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la cápsula del vhb | |
| BR112019004560A2 (pt) | tratamento combinado com agonista de tlr7 e um inibidor de formação de capsídeo de hbv | |
| AR114551A1 (es) | COMPOSICIONES DE AGENTES DE ARNhd CONTRA EL VIRUS DE HEPATITIS B (HBV) Y MÉTODOS PARA SU USO | |
| CL2020002563A1 (es) | Uso de inhibidores de fubp1 para el tratamiento de infección de virus de hepatitis b | |
| AR088580A1 (es) | Metodos y composiciones para tratar el virus de la hepatitis c | |
| BR112018009009A2 (pt) | terapia combinada de um inibidor de formação de capsídeo hbv e um interferon | |
| BR0111732A (pt) | Prodrogas de 2-deóxi-beta-l-nucleosìdeos | |
| AR123345A1 (es) | Una composición farmacéutica para prevenir, aliviar o tratar infección por coronavirus | |
| BR112015010461A2 (pt) | usos alternativos para efetores da reunião do hbv | |
| MX2013000242A (es) | Tratamiento de enfermedades relacionadas con el virus de hepatitis c que usa hidroxicloroquina o una combinacion de hidroxicloroquina y un agente antiviral. | |
| BR112022022599A2 (pt) | Métodos de tratamento de covid-19 usando bardoxolona metil ou análogos da mesma | |
| BR112017000320A2 (pt) | métodos para o tratamento de infecções virais de hepatite b e hepatite d | |
| WO2023083906A3 (en) | Pharmaceutical combinations for treatment of hbv | |
| MX2021003150A (es) | Agentes monomericos y multimericos contra el vhb. | |
| UY38436A (es) | Nuevas 6,7-dihidro-4h-pirazolo[1,5-a] pirazinindol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) | |
| MX2020001226A (es) | Una composicion para tratar y/o prevenir la infeccion por el virus de la hepatitis b y su metodo. | |
| MX2022002231A (es) | Composiciones de anticuerpos y metodos para tratar la infeccion por el virus de la hepatitis b. | |
| MX2021010834A (es) | Compuesto y metodo para la prevencion de transmision del virus de influenza. | |
| MX374835B (es) | Analogos de quinazolinona y usos de los analogos de quinazolinona para tratar o prevenir ciertas infecciones virales. |